olmesartan has been researched along with risperidone in 2 studies
| Studies (olmesartan) | Trials (olmesartan) | Recent Studies (post-2010) (olmesartan) | Studies (risperidone) | Trials (risperidone) | Recent Studies (post-2010) (risperidone) |
|---|---|---|---|---|---|
| 841 | 185 | 554 | 6,924 | 1,505 | 2,477 |
| Protein | Taxonomy | olmesartan (IC50) | risperidone (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.015 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0027 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.0097 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 5.2734 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 4.1901 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0167 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0991 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.026 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0096 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.799 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.479 | |
| Histamine H2 receptor | Homo sapiens (human) | 1.483 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.01 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0016 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0057 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.799 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0027 | |
| 5-hydroxytryptamine receptor 2C | Mus musculus (house mouse) | 0.0015 | |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | 0.0105 | |
| 5-hydroxytryptamine receptor 2A | Mus musculus (house mouse) | 0.0015 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.4515 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.024 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.023 | |
| D(2) dopamine receptor | Mus musculus (house mouse) | 0.023 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0154 | |
| 5-hydroxytryptamine receptor 2B | Mus musculus (house mouse) | 0.0015 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.6303 | |
| 5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 0.43 | |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | 4.1901 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 1.6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
2 other study(ies) available for olmesartan and risperidone
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |